S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial

American Journal of Psychiatry

Volumn 167, Issue 8, 2010, Pages 942-948

  Papakostas, George I ^a   Mischoulon, David ^a   Shyu, Irene ^a   Alpert, Jonathan E ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESSNESS; SIDE EFFECT; SOMNOLENCE; VIVID DREAM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; S-ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 77955360283     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.09081198     Document Type: Article

References (16)

1. Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M: Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005; 25:336-341
2. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40
3. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, Mc-Grath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905-1917
4. Papakostas GI, Alpert JE, Fava M: SAMe in the treatment of depression: a comprehensive review of the literature. Curr Psychiatry Rep 2003; 5:460-466
5. Bottiglieri T: S-adenosyl-l-methionine (SAMe): from the bench to the bedside: molecular basis of a pleiotropic molecule. Am J Clin Nutr 2002; 75(suppl):1151S-1157S
6. Hardy M, Coulter I, Morton SC, Favreau J, Swamy V, Chiappelli F, Rossi F, Orshansky G, Jungvig LK, Roth EA, Suttorp MJ, Shekelle P: S-Adenosyl-l- Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease (Publication number, 02-E04). Rockville, Md, Agency for Healthcare Research and Quality, US Department of Health and Human Services, 2002
7. Papakostas GI: The role of S-adenosyl methionine in the treatment of depression. J Clin Psychiatry 2009; 70(suppl 5):18-22
8. Bressa GM: S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994; 154:7-14
9. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
10. Alpert JE, Papakostas G, Mischoulon D, Worthington JJ 3rd, Petersen T, Mahal Y, Burns A, Bottiglieri T, Nierenberg AA, Fava M: S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 2004; 24:661-664
11. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV). Washington, DC, American Psychiatric Publishing, 1994
12. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P, Version 2.0). New York, New York State Psychiatric Institute, Biometrics Research Department, 1995
13. Guy W (ed): Early Clinical Drug Evaluation Program Assessment Manual for Psychopharmacology, Revised (Publication number, 76-338). Rockville, Md, National Institute of Mental Health, 1976
14. Iruela LM, Minguez L, Merino J, Monedero G: Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993; 150:522
15. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC: Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62:1217-1227
16. Alpert JE, Papakostas GI, Mischoulon D: One-carbon metabolism and the treatment of depression: roles of S-adenosyl-L-methionine and folate, in Natural Medications for Psychiatric Disorders: Considering the Alternatives, 2nd ed. Edited by Mischoulon D, Rosenbaum J. Philadelphia, Lippincott Williams and Wilkins, 2008, pp 68-83